Pharmacopsychiatry 2015; 25 - A17
DOI: 10.1055/s-0035-1557955

Altered myelination in schizophrenia: Evidence from animal models and human cohorts

M D Filiou 1, P Wood 2, L Teplytska 1, D Otte 3, A Zimmer 3, C W Turck 1
  • 1Max Planck Institute of Psychiatry, Munich, Germany
  • 2Lincoln Memorial University, Harrogate, TN
  • 3Institute of Molecular Psychiatry, University of Bonn, Germany

Although myelination pathways have been linked to schizophrenia pathophysiology, the underlying molecular mechanisms are incompletely understood. To further investigate the role of myelination in schizophrenia, we analyzed brain tissue from the G72 mouse model of schizophrenia-like symptoms [1] and schizophrenia patients using quantitative proteomics, metabolomics and lipidomics platforms [2]. We identified expression level alterations in myelination-related proteins and lipids as well as changes in oxidative stress pathways both in mouse and human brain. We then validated selected alterations by immunochemical and enyzmatic assays [3,4]. Our findings highlight the importance of myelination in schizophrenia pathobiology.

This study was supported by NGFN, Max Planck Society

References

[1] Otte et al, Neuropsychopharmacology 2011; 36:2233–43 [2] Filiou and Turck Methods Mol Biol 2012; 829:531–9 [3] Filiou et al. J Psychiatr Res 2012; 46:1359–65 [4] Wood et al. Schizophrenia Res 2014; 159:365–9